#Interferon-free

With interferon quickly becoming a thing of the past, what kind of side effects still remain in the new hepatitis C regimens?

Those with early cirrhosis, hoping to stall further deterioration don’t have the luxury of time. Fortunately, there are options for these pati...

With the FDA approval of Sovaldi and Olysio, many people with hepatitis C, including those coinfected with HIV, will likely line up for...

BMS has submitted for approval in Japan daclatasvir and asunaprevir as the world’s first interferon- and ribavirin-free hep C treatment.

Gilead Sciences has planned a $47 million expansion of its Canadian pharmaceutical plant after its hepatitis C drug sofosbuvir moved closer to...

New hep C drugs are likely hitting the market in the very near future. But how long until interferon can be sent packing?

Faldaprevir and deleobuvir, plus ribavirin, cured genotype 1 of hepatitis C virus (HCV) in 52 to 69 percent of study participants in a recent...

Preparing for a great revolution in hepatitis C care, major pharmaceutical companies are in a mad dash toward achieving blockbuster status.

A cheap, generic anti-viral. It turns out that even with all the advances drug makers are realizing in interferon-free drug combinations, riba...

Promising Phase III results from a trial of Gilead Sciences’s hepatitis C antiviral sofosbuvir open the door for regulatory filing this...

The hepatitis C pipeline: huge changes on the horizon

Antiviral therapies faldaprevir and BI 207127 are safe and effective among people with hepatitis C virus, including those with advanced liver...

A combination of daclatasvir and sofosbuvir produced cures in more than 93 percent of hepatitis C patients, with or without the addition of ri...

Danoprevir and mericitabine, two experimental hepatitis C therapies, proved safe and effective among patients with previous treatment experien...

Abbott Laboratories’ three-drug regimen cured 97 percent of treatment-naive hepatitis C patients and 93 percent of those who had failed a prev...

A 24-week, interferon-free regimen pairing two drugs from Bristol-Myers Squibb--60 milligrams (mg) of daclatasvir, a once-daily NS5a...